Detalhe da pesquisa
1.
Effectiveness, safety and quality of life of trifluridine/tipiracil in pretreated patients with metastatic colorectal cancer: Real-world data from the noninterventional TACTIC study in Germany.
Int J Cancer
; 153(6): 1227-1240, 2023 09 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37260368
2.
Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer.
N Engl J Med
; 382(6): 514-524, 2020 02 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31826360
3.
Surveillance of Myelodysplastic Syndrome via Migration Analyses of Blood Neutrophils: A Potential Prognostic Tool.
J Immunol
; 201(12): 3546-3557, 2018 12 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30446567
4.
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.
N Engl J Med
; 375(18): 1738-1748, 2016 11 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-27717303
5.
A randomized phase II study of paclitaxel alone versus paclitaxel plus sorafenib in second- and third-line treatment of patients with HER2-negative metastatic breast cancer (PASO).
BMC Cancer
; 17(1): 499, 2017 Jul 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-28743247
6.
Disease-free survival as a surrogate for overall survival in HR+/HER2- early breast cancer: A correlation analysis.
Eur J Cancer
; 202: 113977, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38460476
7.
Efficacy, safety, and prognosis prediction in patients treated with ribociclib in combination with letrozole: Final results of phase 3b RIBECCA study in hormone receptor positive, human epidermal growth factor receptor-2 negative, locally advanced or metastatic breast cancer.
Eur J Cancer
; 198: 113480, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38154393
8.
Quality-Adjusted Survival with Ribociclib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Postmenopausal Women with HR±HER2- Advanced Breast Cancer in the MONALEESA-3 Trial.
Clin Breast Cancer
; 22(4): 326-335, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35034858
9.
Real-world patient-reported outcomes of breast cancer or prostate cancer patients receiving antiresorptive therapy for bone metastases: Final results of the PROBone registry study.
J Bone Oncol
; 33: 100420, 2022 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-35340302
10.
Biomarker testing in non-small cell lung cancer in routine care: Analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315).
Lung Cancer
; 152: 174-184, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33358484
11.
A multicentric observational trial of pegylated liposomal doxorubicin for metastatic breast cancer.
BMC Cancer
; 10: 2, 2010 Jan 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-20047698
12.
Effectiveness and Tolerability of Nab-paclitaxel in Younger versus Elderly Patients With Metastatic HR-positive/HER2-negative Breast Cancer: Results From the Noninterventional, Prospective Study NABUCCO.
Clin Breast Cancer
; 20(3): e315-e326, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32273207
13.
Association of Disease Progression With Health-Related Quality of Life Among Adults With Breast, Lung, Pancreatic, and Colorectal Cancer.
JAMA Netw Open
; 3(3): e200643, 2020 03 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32154886
14.
Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study.
Breast
; 54: 148-154, 2020 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-33065342
15.
Final Effectiveness and Safety Results of NABUCCO: Real-World Data From a Noninterventional, Prospective, Multicenter Study in 697 Patients With Metastatic Breast Cancer Treated With nab-Paclitaxel.
Clin Breast Cancer
; 18(6): e1323-e1337, 2018 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-30100104
16.
Changes in Treatment Reality and Survival of Patients With Advanced Clear Cell Renal Cell Carcinoma - Analyses From the German Clinical RCC-Registry.
Clin Genitourin Cancer
; 16(6): e1101-e1115, 2018 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-30061035
17.
Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3.
J Clin Oncol
; 36(24): 2465-2472, 2018 08 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-29860922
18.
Survival of Patients With Advanced or Metastatic Renal Cell Carcinoma in Routine Practice Differs From That in Clinical Trials-Analyses From the German Clinical RCC Registry.
Clin Genitourin Cancer
; 15(2): e209-e215, 2017 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-27720164
19.
Corrigendum to "Biomarker testing in non-small cell lung cancer in routine care: Analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP registry (AIO-TRK-0315)" [Lung Cancer 152 (2021) 174-184].
Lung Cancer
; 157: 167, 2021 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-34049721
20.
CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.
J Clin Oncol
; 33(14): 1564-73, 2015 May 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-25605838